Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removalA A Adjei, I I Budihardjo, E K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemiaE K Rowinsky, S H Kaufmann, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedulesE K Rowinsky, D A Noe, L B Grochow, et al.
Human Gene Therapy|March 1, 1995
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinomaA J Berns, S Clift, L K Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenaseS D Baker, S P Khor, A A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracilS D Baker, R B Diasio, S O'Reilly, et al.
Journal of the National Cancer Institute|June 19, 1996
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic functionS O'Reilly, E Rowinsky, W Slichenmyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 1990
Hypersensitivity reactions from taxolR B Weiss, R C Donehower, P H Wiernik, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removalA A Adjei, I I Budihardjo, E K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemiaE K Rowinsky, S H Kaufmann, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedulesE K Rowinsky, D A Noe, L B Grochow, et al.
Human Gene Therapy|March 1, 1995
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinomaA J Berns, S Clift, L K Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenaseS D Baker, S P Khor, A A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracilS D Baker, R B Diasio, S O'Reilly, et al.
Journal of the National Cancer Institute|June 19, 1996
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic functionS O'Reilly, E Rowinsky, W Slichenmyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 1990
Hypersensitivity reactions from taxolR B Weiss, R C Donehower, P H Wiernik, et al.
Pageof 13